Neuroblastoma: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 200+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

No stopped trial with a stated reason in this view.

Trials whose registry record says individual participant data (IPD) will be shared.

• Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms

  NCT01005654· National Cancer Institute (NCI)· Source

• Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors

  NCT06176989· National Cancer Institute (NCI)· Source

• Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse

  NCT07437963· National Cancer Institute (NCI)· Source

• A Study of Avutometinib for People With Solid Tumor Cancers

  NCT06104488· Memorial Sloan Kettering Cancer Center· Source

• GD2IL18CART Combined With Bevacizumab for Relapsed and Refractory GD2-positive Solid Tumors

  NCT07897968· Universität Münster· Source

• A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors

  NCT06041516· National Cancer Institute (NCI)· Source

• Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

  NCT06395103· Merck Sharp & Dohme LLC· Source

• Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

  NCT06172296· National Cancer Institute (NCI)· Source

• Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma

  NCT06995872· National Cancer Institute (NCI)· Source

• Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

  NCT04284774· National Cancer Institute (NCI)· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 15
• Organoids 2
• Mendelian Randomization Analysis 5
• CRISPR-Cas Systems 5
• Gene Expression Profiling 44
• Sequence Analysis, RNA 5
• Whole Genome Sequencing 4
• Proteomics 20
• Metabolomics 12
• Mass Spectrometry 10
• Flow Cytometry 19
• Immunohistochemistry 20
• Liquid Biopsy 2
• Circulating Tumor DNA 3
• Xenograft Model Antitumor Assays 65
• Positron-Emission Tomography 14
• Magnetic Resonance Imaging 20
• Machine Learning 10
• Deep Learning 4
• Cohort Studies 8
• Genome-Wide Association Study 5

See which targets of this disease your abstract mentions, and go to the people working on them.